Reverx

Reverx is a preclinical-stage biotechnology company focused on developing first-in-class small molecule inhibitors targeting the p62 (SQSTM1) protein. Co-founded by Dr. Michael Karin, a renowned expert in inflammation and cancer signaling, the company leverages its proprietary platform to address unmet needs in oncology and fibrotic diseases. Its lead programs are directed toward the treatment of multiple myeloma and liver diseases, including non-alcoholic steatohepatitis (NASH) and liver fibrosis. By modulating the p62-mediated signaling pathways, Reverx aims to disrupt key mechanisms driving tumor growth and tissue scarring. The company's research is rooted in deep mechanistic understanding of autophagy and proteostasis.